The Latest Breaking News from JJ.

Biotech stocks offers the potential for significant returns driven by breakthrough discoveries and advancements in healthcare, agriculture, and other industries.

Editorial: Britain is pushing for patent changes that could increase the cost of Indian generic drugs, diverting more of the NHS budget to big pharma

Eight Dow Jones stock report earnings this week. Several, including Verizon and 3M, are in buy zones or near buy points.

High yields aren't the only reason to buy shares of dividend-paying stocks. For investors seeking quality dividend stocks for passive income, here's a look at two companies with long track records of raising shareholder payouts.

Cancer-focused biotech companies Ambrx and Harpoon snapped up a pair of takeover deals. AMAM stock and HARP stock soared.

Scientists have offered a new explanation for why COVID-19 vaccines that contained adenoviruses carried a rare-but-serious risk of blood clotting.

The exit of a Johnson & Johnson exec raises an age-old question about women's ambition.

Joe Wolk, with J&J for over 25 years, talks about his path and the company's focus on innovation.

In a series of moves experts say signal a shift in how developing countries deal with pharmaceuticals, South Africa, Colombia and others have recently adopted a more combative approach towards drugmakers, pushing back on policies that deny treatment to millions of people with tuberculosis and HIV

The legendary value investor slashed two consistent dividend-paying stocks from Berkshire Hathaway's portfolio in the latest quarter, according to regulatory filings.

This week’s episode of Fortune‘s Leadership Next podcast features conversations from the Fortune CEO Initiative conference.